CGON earnings date and last-quarter result: next report 2026-08-07, last quarter miss, P/E -29.62. Updated 2026-07-23.
CG Oncology (CGON) Research Hub
CG Oncology (CGON) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 61.56 USD (-0.24%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -29.62, market cap 6.21B. This hub links to the full technical, earnings and options research available for CGON.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 61.56 USD (-0.24%) |
| 52-week range | 59.14 USD – 80.97 USD |
| Trend regime | Range |
| 14-day RSI | 40 (Bearish) |
| Trailing P/E | -29.62 |
| Market cap | 6.21B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-07 |
Available research for CGON
Covered Call on CGON: how it works, illustrative setup around the real 61.56 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CGON: how it works, illustrative setup around the real 61.56 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CGON: how it works, illustrative setup around the real 61.56 USD price, max profit/loss, breakeven and when to use it. Educational.
CGON technical analysis: range, last 61.56 USD, RSI 40, 52w range 59.14 USD–80.97 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CGON in?
CG Oncology (CGON) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CGON in an uptrend or downtrend?
As of 2026-10-26, CGON is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CGON's trailing P/E ratio?
CGON's trailing P/E is -29.62, with a market cap of 6.21B. See the earnings research page for full valuation detail.
When does CGON next report earnings?
CGON is next scheduled to report earnings on 2026-08-07.